United Therapeutics UTHR Inventory Write-Down

Segments

Tyvaso DPI$39.2M+576%

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Market cap$23B+84.1%

P/E17.9×+7.8×

P/S7.3×+3.2×

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×